NVCT — Nuvectis Pharma, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2022-02-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on NVCT
| date | signal | measured base rate |
|---|---|---|
| 2026-06-29 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-05-15 | Institutional holders jumped in a quarter ownership | -0.52% over 21 days · t = -0.38 · n = 1,553 not distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-03 | Carson Michael J. Vice President, Finance | Grant or award | 30.0K | 0.00 | 0 |
| 2026-06-30 | Mosseri Marlio Charles 10% owner | Open-market purchase | 50.0K | 18.32 | 916.0K |
| 2026-06-30 | BENTSUR RON Chairman & CEO | Open-market purchase | 12.5K | 20.00 | 250.0K |
| 2026-06-11 | Sanchez Juan Director | Grant or award | 35.0K | 0.00 | 0 |
| 2026-06-11 | Hoberman Kenneth Director | Grant or award | 35.0K | 0.00 | 0 |
| 2026-06-11 | Oliviero James F III Director | Grant or award | 35.0K | 0.00 | 0 |
| 2026-06-11 | Kaplan Matthew L. Director | Grant or award | 35.0K | 0.00 | 0 |
| 2026-01-06 | Carson Michael J. Vice President, Finance | Grant or award | 61.2K | 0.00 | 0 |
| 2026-01-06 | Poradosu Enrique Chief Science & Business Off | Grant or award | 150.0K | 0.00 | 0 |
| 2026-01-06 | Shemesh Shay Chief Dev. & Ops. Officer | Grant or award | 150.0K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 5.9M | 764.4K |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1M | 659.9K |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 5.0M | 651.8K |
| Occam Crest Management LP | 3.1M | 407.1K |
| GEODE CAPITAL MANAGEMENT, LLC | 3.0M | 384.1K |
| BALDWIN WEALTH PARTNERS LLC/MA | 2.9M | 378.6K |
| STATE STREET CORP | 1.3M | 166.5K |
| NORTHERN TRUST CORP | 960.2K | 124.2K |
| VANGUARD FIDUCIARY TRUST CO | 887.7K | 114.8K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 813.9K | 105.3K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Nuvectis Pharma, Inc. (NVCT) filed form 8-K · 2026-08-21 · SEC EDGAR
Ask the AI about NVCT
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →